IP Library Granted Patent US 9,884,017
Granted Patent B2
US 9,884,017 · App. 15/639,114 · Granted Feb 6, 2018

Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof

Inventors: Dov Tamarkin (Ness Ziona, IL); David Schuz (Gimzu, IL); Tal Berman (Rishon Le Ziyyon, IL); Yohan Hazot (Rehovot, IL)
Assignee: FOAMIX PHARMACEUTICALS LTD.
A61K9/122A61K8/046A61K8/46A61K9/0014A61K47/14A61K47/20A61K47/26A61K47/38A61Q19/00A61K2800/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,017
App. No.
15/639,114
Granted
Feb 6, 2018
Kind
B2
Abstract

The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.

Claims (28)

1. A foamable composition formulated for skin delivery of an active agent comprising:

a minocycline in a therapeutically effective amount of about 1 to about 5% by weight of the composition;

a short chain alcohol comprising ethanol;

about 12% to about 30% by weight of the composition of a protic polar solvent comprising propylene glycol;

a polymeric agent comprising a cellulose ether;

a modulating agent comprises an antioxidizing agent;

a metal;

an essential oil;

wherein the foamable composition is surfactant free;

and wherein the composition is waterless and essentially free of fatty alcohol.

2. The foamable composition according to claim 1 , wherein the minocycline is a minocycline hydrochloride.

3. The foamable composition according to claim 1 , wherein the therapeutically effective amount is about 1%.

4. The foamable composition according to claim 1 , wherein the therapeutically effective amount is about 4%.

5. The foamable composition according to claim 1 , wherein the short chain alcohol is present in an amount of at least 55% by weight of the composition.

6. The foamable composition according to claim 1 , wherein the cellulose ether is a hydroxypropyl cellulose.

7. The foamable composition according to claim 1 , wherein the modulating agent is present in an amount ranging from about 0.1% to about 10% by weight of the composition.

8. The foamable composition according to claim 7 , wherein the modulating agent is present in an amount ranging from about 1% to about 5% by weight of the composition.

9. The foamable composition according to claim 1 , wherein the cellulose ether is present in an amount ranging from about 0.5% to about 1% by weight of the composition.

10. The foamable composition according to claim 1 , wherein:

the minocycline is minocycline hydrochloride; and

the cellulose ether is a hydroxypropyl cellulose.

11. The foamable composition according to claim 10 , wherein:

the ethanol is present in an amount of at least 55% by weight of the composition;

the hydroxypropyl cellulose is present in an amount of about 0.5% to about 1% by weight of the composition; and

the modulating agent is present in an amount ranging from about 0.1% to about 10% by weight of the composition.

12. The foamable composition according to claim 11 , wherein the therapeutically effective amount is about 1% by weight of the composition.

13. The foamable composition according to claim 11 , wherein the therapeutically effective amount is about 4% by weight of the composition.

14. The foamable composition according to claim 1 , wherein the liquefied or compressed gas propellant is present in an amount ranging from about 3% to about 25% by weight of the composition.

Assignments (9)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: VYNE THERAPEUTICS INC.; VYNE PHARMACEUTICALS INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 058925/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: VYNE THERAPEUTICS INC.
To: VYNE PHARMACEUTICALS INC.
Reel/Frame 058463/0167 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →
Continuity (3)
Division 13263201
Provisional Application 61173378 · Apr 28, 2009
Related Publication 20170360705A1 · Dec 21, 2017